FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Brian Gazzard

Research Profile

Disorders

Procedures

Living Beings

HIV-1

Chemicals & Drugs

Concepts & Ideas

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
S Fidler; Martin Fisher; Brian Gazzard; N Gill; L Lazarus; Ruth Lowbury; K Orton; B Osoro; K Radcliffe; Karen E Rogstad; B Smith; J Anderson; Y Azad; D Churchill; V Delpech; C Evans; G Cairns
Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA).
Peter Hayes; Akil Jackson; Jakub Kopycinski; Angela Lombardo; Eddy Sayeed; Andrea von Lieven; Devika Zachariah; James Ackland; Galit Alter; Marta Boffito; Hannah Cheeseman; Amy Chung; Lorna Clark; Josephine H Cox; Len Dally; Patricia E Fast; Brian Gazzard; Dilbinder Gill; Jill Gilmour; Dagna Laufer
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
Mark Gompels; Teresa Hill; Margaret Johnson; Clifford Leen; Chloe Orkin; Andrew Phillips; Deenan Pillay; Frank Post; Caroline Sabin; John Walsh; Jonathan Ainsworth; Jane Anderson; Loveleen Bansi; Andrew De Burgh Thomas; Debbie Dooley; David T Dunn; Philippa Easterbrook; Martin Fisher; Brian Gazzard; Richard Gilson
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Brian Gazzard (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: S Fidler; Martin Fisher; Brian Gazzard; N Gill; L Lazarus; Ruth Lowbury; K Orton; B Osoro; K Radcliffe; Karen E Rogstad; B Smith; J Anderson; Y Azad; D Churchill; V Delpech; C Evans; G Cairns
Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA).
HIV medicine 2013;14(5):259-62.
2013: Peter Hayes; Akil Jackson; Jakub Kopycinski; Angela Lombardo; Eddy Sayeed; Andrea von Lieven; Devika Zachariah; James Ackland; Galit Alter; Marta Boffito; Hannah Cheeseman; Amy Chung; Lorna Clark; Josephine H Cox; Len Dally; Patricia E Fast; Brian Gazzard; Dilbinder Gill; Jill Gilmour; Dagna Laufer
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
Clinical and vaccine immunology : CVI 2013;20(3):397-408.
2012: Mark Gompels; Teresa Hill; Margaret Johnson; Clifford Leen; Chloe Orkin; Andrew Phillips; Deenan Pillay; Frank Post; Caroline Sabin; John Walsh; Jonathan Ainsworth; Jane Anderson; Loveleen Bansi; Andrew De Burgh Thomas; Debbie Dooley; David T Dunn; Philippa Easterbrook; Martin Fisher; Brian Gazzard; Richard Gilson
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?
The Journal of infectious diseases 2012;205(4):540-7.
2012: Brian Gazzard; Christiane Moecklinghoff; Andrew Hill
New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom.
ClinicoEconomics and outcomes research : CEOR 2012;4():193-200.
2012: Akil Jackson; Saye Khoo; Graeme Moyle; Jessica Taylor; George Abongomera; David Back; Laura Dickinson; Brian Gazzard; Keerti Gedela; Marta Boffito
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Antiviral therapy 2012;17(1):19-24.
2012: C Kober; Clifford Leen; Chloe Orkin; Adrian Palfreeman; Andrew N Phillips; F Post; Caroline A Sabin; John Walsh; J Ainsworth; Jane Anderson; L Bansi; Valerie Delpech; D Dunn; Martin Fisher; Brian Gazzard; Richard Gilson; M Gompels; Teresa Hill; Margaret Johnson
Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.
HIV medicine 2012;13(1):73-8.
2011: Akil Jackson; Saye Khoo; Neill Liptrott; Victoria Watson; Deidre Egan; Brian Gazzard; Keerti Gedela; Chris Higgs; Riaz Abbas; David Back; Marta Boffito
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2011;58(5):450-7.
2011: R A Hughes; M A Johnson; Clifford Leen; Chloe Orkin; Andrew N Phillips; Deenan Pillay; J A C Sterne; John Walsh; J Ainsworth; Jane Anderson; L Bansi; D Dunn; Philippa Easterbrook; Martin Fisher; Brian Gazzard; Richard Gilson; M Gompels; Teresa Hill; Caroline A Sabin
Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.
HIV medicine 2011;12(10):583-93.
2011: Jocelyn S Downey; Brian Gazzard; Frances Gotch; Meriem Attaf; Graeme Moyle; Nesrina Imami
T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness.
AIDS (London, England) 2011;25(16):1981-6.
2011: Marta Boffito; Brian Gazzard; Christopher Higgs; Akil Jackson; Saye Khoo; Alieu Amara; David Back; Natalia Seymour; Graeme Moyle
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Antimicrobial agents and chemotherapy 2011;55(9):4218-23.
2011: Neesha Rockwood; Mark Bower; Brian Gazzard; Sundhiya Mandalia; Mark Nelson
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
AIDS (London, England) 2011;25(13):1671-3.
2011: Brian Gazzard; Andrew Hill; Anne Anceau
Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.
Applied health economics and health policy 2011;9(4):217-23.
2011: A Scourfield; L Waters; George Zenon Panos; P Randell; Brian Gazzard; P Holmes; A Jackson; Sundhiya Mandalia; Mark Nelson
Non-cirrhotic portal hypertension in HIV-infected individuals.
International journal of STD & AIDS 2011;22(6):324-8.
2011: Darius Armstrong-James; Justin Stebbing; Laurence John; Andrew Murungi; Mark Bower; Brian Gazzard; Mark Nelson
A trial of caspofungin salvage treatment in PCP pneumonia.
Thorax 2011;66(6):537-8.
2011: L Waters; Martin Fisher; Jane Anderson; C Wood; V Delpech; T Hill; John Walsh; C Orkin; L Bansi; M Gompels; A Phillips; Margaret Johnson; R Gilson; Philippa Easterbrook; Clifford Leen; K Porter; Brian Gazzard; C Sabin
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.
HIV medicine 2011;12(5):289-98.
2011: Deepak Joshi; John O'Grady; Doug Dieterich; Brian Gazzard; Kosh Agarwal
Increasing burden of liver disease in patients with HIV infection.
Lancet 2011;377(9772):1198-209.
2011: Akil Jackson; Antonio D'Avolio; Victoria Watson; Stefano Bonora; David Back; Jessica Taylor; Kostantinos Armenis; Brian Gazzard; Graeme Moyle; Marta Boffito
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
The Journal of antimicrobial chemotherapy 2011;66(4):885-9.
2011: Akil Jackson; Andrew Hill; Rebekah Puls; Laura Else; Janaki Amin; David Back; Enmoore Lin; Saye Khoo; Sean Emery; Roland Morley; Brian Gazzard; Marta Boffito
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
The Journal of antimicrobial chemotherapy 2011;66(3):635-40.
2011: Lucy Garvey; Alan Winston; John Walsh; Frank Post; Kholoud Porter; Brian Gazzard; Martin Fisher; Clifford Leen; Deenan Pillay; Teresa Hill; Margaret Johnson; Richard Gilson; Jane Anderson; Philippa Easterbrook; Loveleen Bansi; Chloe Orkin; Jonathan Ainsworth; Andrew N Phillips; Caroline A Sabin
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2011;18(3):527-34.
2011: L Garvey; Alan Winston; J Walsh; F Post; Kholoud Porter; Brian Gazzard; Martin Fisher; C Leen; D Pillay; T Hill; M Johnson; R Gilson; J Anderson; Philippa Easterbrook; L Bansi; C Orkin; J Ainsworth; A Palfreeman; M Gompels; A N Phillips; C A Sabin
Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.
Neurology 2011;76(8):693-700.
2011: Mark Nelson; Hans-Jürgen Stellbrink; Daniel Podzamczer; Dénes Banhegyi; Brian Gazzard; Andrew Hill; Yvon van Delft; Johan Vingerhoets; Thomas Stark; Stephan Marks
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
AIDS (London, England) 2011;25(3):335-40.
2011: Margaret May; Mark Nelson; Chloe Orkin; Adrian Palfreeman; Andrew Phillips; Kholoud Porter; Frank Post; Jonathan Ainsworth; Jane Anderson; Loveleen Bansi; Valerie Delpech; David Dunn; Martin Fisher; Brian Gazzard; Richard Gilson; Mark Gompels; Teresa Hill; Margaret Johnson; Clifford Leen; John Walsh; Caroline Sabin
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.
BMJ (Clinical research ed.) 2011;343():d6016.
2011: Andrew Scourfield; Laura Waters; Brian Gazzard; Akil Jackson; Mark Nelson
The value of screening HIV-infected individuals for didanosine-related liver disease?
Antiviral therapy 2011;16(6):941-2.
2011: Tristan J Barber; Valerie Delpech; David Dunn; Philippa Easterbrook; Martin Fisher; Brian Gazzard; Anna Maria Geretti; Richard Gilson; Mark Gompels; Teresa Hill; Margaret Johnson; Clifford Leen; Chloe Orkin; Adrian Palfreeman; Andrew N Phillips; Deenan Pillay; Frank Post; Caroline A Sabin; Achim Schwenk; John Walsh; Jane Anderson; Loveleen Bansi
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.
Antiviral therapy 2011;16(6):805-14.
2010: Saliha Yilmaz; Marta Boffito; Sophie Collot-Teixeira; Ferruccio De Lorenzo; Laura Waters; Carl Fletcher; David Back; Anton Pozniak; Brian Gazzard; John L McGregor
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.
Genomics 2010;96(1):57-65.
2010: I Davidson; H Beardsell; B Smith; Sundhiya Mandalia; mark bower; Brian Gazzard; Mark Nelson; J Stebbing
The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.
Antiviral research 2010;86(2):227-9.
2010: Brian Gazzard; Andrew Balkin; Andrew Hill
Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.
AIDS reviews 2010;12(2):67-75.
2010: Wolfgang Stöhr; David Back; David Dunn; Caroline Sabin; Alan Winston; Richard Gilson; Deenan Pillay; Teresa Hill; Jonathan Ainsworth; Brian Gazzard; Clifford Leen; Loveleen Bansi; Martin Fisher; Chloe Orkin; Jane Anderson; Margaret Johnson; Philippa Easterbrook; Sara Gibbons; Saye Khoo
Factors influencing lopinavir and atazanavir plasma concentration.
The Journal of antimicrobial chemotherapy 2010;65(1):129-37.
2009: Siew C Ng; Brian Gazzard
Advances in sexually transmitted infections of the gastrointestinal tract.
Nature reviews. Gastroenterology & hepatology 2009;6(10):592-607.
2009: Marta Boffito; Akil Jackson; Mohammed Lamorde; David Back; Victoria Watson; Jessica Taylor; Laura Waters; David Asboe; Brian Gazzard; Anton Pozniak
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.
Journal of acquired immune deficiency syndromes (1999) 2009;52(2):222-7.
2009: mark bower; Justin Weir; Nicholas Francis; Tom Newsom-Davis; Sam Powles; Tim Crook; Marta Boffito; Brian Gazzard; Mark Nelson
The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.
AIDS (London, England) 2009;23(13):1701-6.
2009: Sandrine Buisson; Adel Benlahrech; Brian Gazzard; Frances Gotch; Peter Kelleher; Steven Patterson
Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.
The Journal of infectious diseases 2009;199(12):1862-71.
2009: Ferruccio De Lorenzo; Marta Boffito; Sophie Collot-Teixeira; Brian Gazzard; John L McGregor; Kevin Shotliff; Han Xiao
Prevention of atherosclerosis in patients living with HIV.
Vascular health and risk management 2009;5(1):287-300.
2009: Samantha J Westrop; Nadeem A Qazi; Jeffrey Pido-Lopez; Mark R Nelson; Brian Gazzard; Frances M Gotch; Nesrina Imami
Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers.
PloS one 2009;4(5):e5474.
2009: Andrew Hill; Will Sawyer; Brian Gazzard
Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.
HIV clinical trials 2009;10(1):1-12.
2009: Caroline A Sabin; Colette J Smith; Valerie Delpech; Jane Anderson; L Bansi; Richard Gilson; A Schwenk; Clifford Leen; Brian Gazzard; Kholoud Porter; N Mackie; Martin Fisher; Chloe Orkin; Margaret Johnson; Philippa Easterbrook; Teresa Hill; Andrew N Phillips
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.
HIV medicine 2009;10(1):35-43.
2008: Joanne Reekie; Amanda Mocroft; Helen Sambatakou; Ladislav Machala; Antonio Chiesi; Jan van Lunzen; Nathan Clumeck; Ole Kirk; Brian Gazzard; Jens D Lundgren
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
AIDS (London, England) 2008;22(17):2381-90.
2008: Mário Guimarães Pessôa; Brian Gazzard; Anna K Huang; Carlos E Brandão-Mello; Isabel Cassetti; Maria Cassia Mendes-Corrêa; Vicente Soriano; Phillip Phiri; Andrea Hall; Helena Brett-Smith
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
AIDS (London, England) 2008;22(14):1779-87.
2008: Geoffrey P Garnett; Brian Gazzard
Risk of HIV transmission in discordant couples.
Lancet 2008;372(9635):270-1.
2008: Brian Gazzard; Nathan Clumeck; A d'Arminio Monforte; J D Lundgren
Indicator disease-guided testing for HIV--the next step for Europe?
HIV medicine 2008;9 Suppl 2():34-40.
2008: K Singh; L Dickinson; A Chaikan; D Back; C Fletcher; Anton Pozniak; G Moyle; Mark Nelson; Brian Gazzard; D Herath; Marta Boffito
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.
Clinical pharmacology and therapeutics 2008;83(6):867-72.
2008: Laura Waters; Sundhiya Mandalia; Paul Randell; Adrian Wildfire; Brian Gazzard; Graeme Moyle
The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(10):1617-23.
2008: mark bower; Justin Stebbing; Mark Tuthill; Victoria Campbell; Johnathan Krell; Paul Holmes; Andrew Ozzard; Mark Nelson; Brian Gazzard; Tom Powles
Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma.
Blood 2008;111(8):3986-90.
2008: Kholoud Porter; Sarah Walker; Teresa Hill; Jane Anderson; Clifford Leen; Margaret Johnson; Brian Gazzard; John Walsh; Martin Fisher; Chloe Orkin; Achim Schwenk; Richard Gilson; Philippa Easterbrook; Valerie Delpech; Caroline A Sabin
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.
Journal of acquired immune deficiency syndromes (1999) 2008;47(2):202-5.
2008: Loveleen K Bansi; Andrew A Benzie; Andrew N Phillips; Simon Portsmouth; Teresa Hill; Clifford Leen; Achim Schwenk; Margaret Johnson; Jane Anderson; Richard Gilson; Philippa Easterbrook; Brian Gazzard; Martin Fisher; Chloe Orkin; Kholoud Porter; Deenan Pillay; Graham P Taylor; John C Walsh; Caroline A Sabin
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
AIDS (London, England) 2008;22(3):349-56.
2008: Marta Boffito; Laura Else; David Back; Jessica Taylor; Saye Khoo; Marta Sousa; Anton Pozniak; Brian Gazzard; Graeme Moyle
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Antiviral therapy 2008;13(7):901-7.
2008: Philippa J Easterbrook; Andrew N Phillips; Teresa Hill; Ryanne Matthias; Martin Fisher; Brian Gazzard; Richard Gilson; George Scullard; Margaret Johnson; D T Dunn; Chloe Orkin; Jane Anderson; A Schwenk; Clifford Leen; Caroline A Sabin
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
HIV medicine 2008;9(1):47-56.
2008: Laura Waters; Mark Nelson; Sundhiya Mandalia; mark bower; Tom Powles; Brian Gazzard; Justin Stebbing
The risks and incidence of K65R and L74V mutations and subsequent virologic responses.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(1):96-100.
2008: José Ramon Arribas; Anton L Pozniak; Joel E Gallant; Edwin DeJesus; Brian Gazzard; Rafael E Campo; Shan-Shan Chen; Damian McColl; Charles Holmes; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Journal of acquired immune deficiency syndromes (1999) 2008;47(1):74-8.
2007: Andrew N Phillips; Clifford Leen; Alan Wilson; Jane Anderson; David Dunn; Achim Schwenk; Chloe Orkin; Teresa Hill; Martin Fisher; John Walsh; Deenan Pillay; Loveleen Bansi; Brian Gazzard; Philippa Easterbrook; Richard Gilson; Margaret Johnson; Caroline A Sabin
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.
Lancet 2007;370(9603):1923-8.
2007: Laura Waters; Sundhiya Mandalia; Brian Gazzard; Mark Nelson
Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
AIDS (London, England) 2007;21(18):2533-4.
2007: Sally-Ann Clark; S L Martin; A Pozniak; alan steel; B Ward; J Dunning; Don C Henderson; Mark Nelson; Brian Gazzard; Peter Kelleher
Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease.
Clinical and experimental immunology 2007;150(2):238-44.
2007: Justin Stebbing; Bif Nathan; Rachael Jones; Alex McKenna; Tom Powles; mark bower; Paul Holmes; Brian Gazzard; Mark Nelson
Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
AIDS (London, England) 2007;21(13):1826-8.
2007: Andrew N Phillips; Brian Gazzard; Richard Gilson; Philippa Easterbrook; Margaret Johnson; John Walsh; Clifford Leen; Martin Fisher; Chloe Orkin; Jane Anderson; Deenan Pillay; Valerie Delpech; Caroline Sabin; Achim Schwenk; David Dunn; Mark Gompels; Teresa Hill; Kholoud Porter; Abdel G Babiker
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
AIDS (London, England) 2007;21(13):1717-21.
2007: Marta Boffito; Alan Winston; Akil Jackson; Carl Fletcher; Anton Pozniak; Mark Nelson; Graeme Moyle; Izabela Tolowinska; Richard Hoetelmans; Diego Miralles; Brian Gazzard
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
AIDS (London, England) 2007;21(11):1449-55.
2007: Andrew A Benzie; Loveleen K Bansi; Caroline A Sabin; Simon Portsmouth; Teresa Hill; Margaret Johnson; Richard Gilson; Philippa Easterbrook; Brian Gazzard; Martin Fisher; Chloe Orkin; David Dunn; Valerie Delpech; Graham P Taylor; John C Walsh; Andrew N Phillips
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.
AIDS (London, England) 2007;21(11):1423-30.
2007: Adrian Wildfire; Justin Stebbing; Brian Gazzard
Rights theory in a specific healthcare context: "speaking ill of the dead".
Postgraduate medical journal 2007;83(981):473-7.
2007: J Wang; A Ozzard; M Nathan; M Atkins; Mark Nelson; Brian Gazzard; mark bower
The significance of Epstein-Barr virus detected in the cerebrospinal fluid of people with HIV infection.
HIV medicine 2007;8(5):306-11.
2007: Guglielmo Rosignoli; Alison Cranage; Catherine Burton; Mark Nelson; alan steel; Brian Gazzard; Frances Gotch; Nesrina Imami
Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients.
AIDS (London, England) 2007;21(10):1379-81.
2007: Mark R Nelson; Christine Katlama; Julio S G Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS (London, England) 2007;21(10):1273-81.
2007: Melanie Hart; alan steel; Sally-Ann Clark; Graeme Moyle; Mark Nelson; Don C Henderson; Robert Wilson; Frances Gotch; Brian Gazzard; Peter Kelleher
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(12):8212-20.
2007: E E Low; B Nathan; B M Killingley; Mark Nelson; Brian Gazzard
Listeriosis associated with upper gastrointestinal endoscopy in an HIV-infected patient.
International journal of STD & AIDS 2007;18(6):431-2.
2007: Justin Stebbing; Adam Sanitt; Alastair Teague; Tom Powles; Mark Nelson; Brian Gazzard; mark bower
Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2230-5.
2007: W Stöhr; David Dunn; Kholoud Porter; Teresa Hill; Brian Gazzard; John Walsh; Richard Gilson; Philippa Easterbrook; Martin Fisher; Ma Johnson; Valerie Delpech; An Phillips; Caroline Sabin
CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003.
HIV medicine 2007;8(3):135-41.
2007: Lauro J Waters; Graeme Moyle; Stefano Bonora; Antonio D'Avolio; Laura Else; Sundhiya Mandalia; Anton Pozniak; Mark Nelson; Brian Gazzard; David Back; Marta Boffito
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Antiviral therapy 2007;12(5):825-30.
2007: Gareth A D Hardy; Nesrina Imami; Mark R Nelson; Ann K Sullivan; Ron Moss; Marlén M I Aasa-Chapman; Brian Gazzard; Frances M Gotch
A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.
Journal of immune based therapies and vaccines 2007;5():6.
2007: Martin R Goodier; Christopher M Mela; alan steel; Brian Gazzard; mark bower; Frances Gotch
NKG2C+ NK cells are enriched in AIDS patients with advanced-stage Kaposi's sarcoma.
Journal of virology 2007;81(1):430-3.
2006: Anton L Pozniak; Joel E Gallant; Edwin DeJesus; José Ramon Arribas; Brian Gazzard; Rafael E Campo; Shan-Shan Chen; Damian McColl; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Journal of acquired immune deficiency syndromes (1999) 2006;43(5):535-40.
2006: Brian Gazzard; A J Bernard; Marta Boffito; Duncan Churchill; S Edwards; N Fisher; Anna Maria Geretti; Margaret Johnson; Clifford Leen; B Peters; Anton Pozniak; J Ross; John Walsh; Edmund Wilkins; Mike Youle
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).
HIV medicine 2006;7(8):487-503.
2006: Jennifer Ford; Marta Boffito; Desmond Maitland; Andrew Hill; David Back; Saye Khoo; Mark Nelson; Graeme Moyle; Brian Gazzard; Anton Pozniak
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
The Journal of antimicrobial chemotherapy 2006;58(5):1009-16.
2006: mark bower; Tom Powles; Mark Nelson; Sundhiya Mandalia; Brian Gazzard; Justin Stebbing
Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma.
Journal of the National Cancer Institute 2006;98(15):1088-91.
2006: Rachael Jones; Brian Gazzard
The cost of antiretroviral drugs and influence on prescribing policies.
International journal of STD & AIDS 2006;17(8):499-506.
2006: Marta Boffito; Desmond Maitland; Laura Dickinson; David Back; Andrew Hill; Carl Fletcher; Graeme Moyle; Mark Nelson; Brian Gazzard; Anton Pozniak
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
AIDS research and human retroviruses 2006;22(8):749-56.
2006: Justin Stebbing; mark bower; Sundhiya Mandalia; Mark Nelson; Brian Gazzard
Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality.
Clinical and experimental immunology 2006;145(2):271-6.
2006: alan steel; Sally-Ann Clark; Ian Teo; Sunil Shaunak; Mark Nelson; Brian Gazzard; Peter Kelleher
No change to HIV-1 latency with valproate therapy.
AIDS (London, England) 2006;20(12):1681-2.
2006: Alan Winston; David Back; Carl Fletcher; Lesley Robinson; Jennifer Unsworth; Izabela Tolowinska; Malte Schutz; Anton L Pozniak; Brian Gazzard; Marta Boffito
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
AIDS (London, England) 2006;20(10):1401-6.
2006: Justin Stebbing; Adam Sanitt; Mark Nelson; Tom Powles; Brian Gazzard; mark bower
A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy.
Lancet 2006;367(9521):1495-502.
2006: Justin Stebbing; mark bower; P Holmes; Brian Gazzard; Mark Nelson
A single centre cohort experience with a new once daily antiretroviral drug.
Postgraduate medical journal 2006;82(967):343-6.
2006: Graeme Moyle; Carl Fletcher; H Brown; Sundhiya Mandalia; Brian Gazzard
Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen.
HIV medicine 2006;7(4):243-7.
2006: Alan Winston; Nimesh Patel; David Back; Saye Khoo; Steve Bulbeck; Sundhiya Mandalia; Anton L Pozniak; Mark Nelson; Graeme Moyle; Brian Gazzard; Marta Boffito
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.
Journal of acquired immune deficiency syndromes (1999) 2006;41(5):675-6.
2006: Rachael Jones; Brian Gazzard
HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors.
Expert review of anti-infective therapy 2006;4(2):303-12.
2006: Justin Stebbing; Danish Mazhar; R Lewis; Carlo Palmieri; E Hatzimichael; Mark Nelson; Brian Gazzard; mark bower
The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(3):503-6.
2006: Joel E Gallant; Edwin DeJesus; José Ramon Arribas; Anton L Pozniak; Brian Gazzard; Rafael E Campo; Biao Lu; Damian McColl; Steven Chuck; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
The New England journal of medicine 2006;354(3):251-60.
2006: Graeme Moyle; Christopher Higgs; Alastair Teague; Sundhiya Mandalia; Mark Nelson; Margaret Johnson; Martin Fisher; Brian Gazzard
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Antiviral therapy 2006;11(1):73-8.
2005: Colette J Smith; Andrew N Phillips; Teresa Hill; Martin Fisher; Brian Gazzard; Kholoud Porter; Richard Gilson; Philippa Easterbrook; Ryanne Matthias; George Scullard; Margaret A Johnson; Caroline A Sabin
The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.
The Journal of infectious diseases 2005;192(8):1387-97.
2005: A Pires; M Nelson; A L Pozniak; M Fisher; Brian Gazzard; F Gotch; Nesrina Imami
Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy.
Journal of immune based therapies and vaccines 2005;3():7.
2005: Justin Stebbing; Laura Waters; Sundhiya Mandalia; mark bower; Mark Nelson; Brian Gazzard
Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(6):906-11.
2005: Justin Stebbing; S Sawleshwarkar; Christos Michailidis; R Jones; mark bower; Sundhiya Mandalia; Mark Nelson; Brian Gazzard
Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people.
Postgraduate medical journal 2005;81(959):586-8.
2005: mark bower; Brian Gazzard; Sundhiya Mandalia; Tom Newsom-Davis; Christina Thirlwell; Tony Dhillon; Anne Marie Young; Tom Powles; Andrew Gaya; Mark Nelson; Justin Stebbing
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
Annals of internal medicine 2005;143(4):265-73.
2005: Laura Waters; Justin Stebbing; Sundhiya Mandalia; Anne Marie Young; Mark Nelson; Brian Gazzard; mark bower
Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort study.
International journal of cancer. Journal international du cancer 2005;116(1):161-3.
2005: Adrian Woolfson; Justin Stebbing; Brian D M Tom; Kerryn Stoner; Walter R Gilks; David P Kreil; Stephen P Mulligan; Larissa Belov; Jeremy S Chrisp; Will Errington; Adrian Wildfire; Wendy N Erber; mark bower; Brian Gazzard; Richard I Christopherson; Mike A Scott
Conservation of unique cell-surface CD antigen mosaics in HIV-1-infected individuals.
Blood 2005;106(3):1003-7.
2005: Desmond Maitland; Graeme Moyle; James Hand; Sundhiya Mandalia; Marta Boffito; Mark Nelson; Brian Gazzard
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
AIDS (London, England) 2005;19(11):1183-8.
2005: Victoria Latham; Justin Stebbing; Sundhiya Mandalia; Christos Michailidis; Elizabeth Davies; mark bower; Brian Gazzard; Mark Nelson
Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.
The Journal of antimicrobial chemotherapy 2005;56(1):186-9.
2005: Steve Patterson; Heather Donaghy; Parisa Amjadi; Brian Gazzard; Frances Gotch; Peter Kelleher
Human BDCA-1-positive blood dendritic cells differentiate into phenotypically distinct immature and mature populations in the absence of exogenous maturational stimuli: differentiation failure in HIV infection.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(12):8200-9.
2005: M-Y Tung; Sundhiya Mandalia; mark bower; Brian Gazzard; Mark Nelson
The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
HIV medicine 2005;6(3):151-4.
2005: Marta Boffito; Desmond Maitland; Laura Dickinson; David Back; Andrew Hill; Carl Fletcher; Graeme Moyle; Mark Nelson; Brian Gazzard; Anton Pozniak
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
The Journal of antimicrobial chemotherapy 2005;55(4):542-5.
2005: Caroline A Sabin; Teresa Hill; Fiona C Lampe; Ryanne Matthias; Sanjay Bhagani; Richard Gilson; Mike Youle; Margaret A Johnson; Martin Fisher; George Scullard; Philippa Easterbrook; Brian Gazzard; Andrew N Phillips
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
BMJ (Clinical research ed.) 2005;330(7493):695.
2005: Andrew N Phillips; David Dunn; Caroline Sabin; Anton Pozniak; Ryanne Matthias; Anna Maria Geretti; John Clarke; Duncan Churchill; Ian Williams; Teresa Hill; Hannah Green; Kholoud Porter; George Scullard; Margaret Johnson; Philippa Easterbrook; Richard Gilson; Martin Fisher; Clive Loveday; Brian Gazzard; Deenan Pillay
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
AIDS (London, England) 2005;19(5):487-94.
2005: Chloe Orkin; Justin Stebbing; Mark Nelson; mark bower; Margaret Johnson; Sundhiya Mandalia; Rachael Jones; Graeme Moyle; Martin Fisher; Brian Gazzard
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
The Journal of antimicrobial chemotherapy 2005;55(2):246-51.
2005: Marta Boffito; David Back; Meredith Stainsby-Tron; Andrew Hill; Giovanni Di Perri; Graeme Moyle; Mark Nelson; Jaqui Tomkins; Brian Gazzard; Anton Pozniak
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
British journal of clinical pharmacology 2005;59(1):38-42.
2004: mark bower; Tom Powles; Tom Newsom-Davis; Christina Thirlwell; Justin Stebbing; Sundhiya Mandalia; Mark Nelson; Brian Gazzard
HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?
Journal of acquired immune deficiency syndromes (1999) 2004;37(5):1563-5.
2004: Rachael Jones; Justin Stebbing; Mark Nelson; Graeme Moyle; mark bower; Sundhiya Mandalia; Brian Gazzard
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.
Journal of acquired immune deficiency syndromes (1999) 2004;37(4):1489-95.
2004: Gareth A D Hardy; Nesrina Imami; Ann K Sullivan; Mark R Nelson; Brian Gazzard; Frances M Gotch
Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses.
AIDS (London, England) 2004;18(16):2199-202.
2004: Justin Stebbing; mark bower; Brian Gazzard; Adrian Wildfire; Hardev Pandha; Angus Dalgleish; J Spicer
The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressors.
Clinical and experimental immunology 2004;138(2):312-6.
2004: Marta Boffito; Laura Dickinson; Andrew Hill; David Back; Graeme Moyle; Mark Nelson; Christopher Higgs; Carl Fletcher; Brian Gazzard; Anton Pozniak
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2004;37(3):1376-84.
2004: mark bower; Neil McCall-Peat; Natalie Ryan; Liz Davies; Anne Marie Young; Srirupa Gupta; Mark Nelson; Brian Gazzard; Justin Stebbing
Protease inhibitors potentiate chemotherapy-induced neutropenia.
Blood 2004;104(9):2943-6.
2004: Justin Stebbing; Brian Gazzard; Steve Patterson; mark bower; Mark Nelson; Agamemnon Epenetos; Graham Ogg; Frances Gotch; Philip Savage
Simplified one-step antibody-HLA directed expansion of HIV-specific cytotoxic T lymphocytes: a system suited for use in vivo.
AIDS (London, England) 2004;18(15):2099-101.
2004: Colette J Smith; Schlomo Staszewski; Caroline A Sabin; Mark Nelson; Brenda Dauer; Peter Gute; Margaret A Johnson; Andrew N Phillips; Brian Gazzard
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals.
Journal of acquired immune deficiency syndromes (1999) 2004;37(1):1155-9.
2004: Tom Newsom-Davis; mark bower; Adrian Wildfire; Christina Thirlwell; Mark Nelson; Brian Gazzard; Justin Stebbing
Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels.
Leukemia & lymphoma 2004;45(9):1939-41.
2004: L Waters; Justin Stebbing; R Jones; Christos Michailidis; S Sawleshwarkar; Sundhiya Mandalia; mark bower; Mark Nelson; Brian Gazzard
A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts.
The Journal of antimicrobial chemotherapy 2004;54(2):503-7.
2004: Jennifer Ford; Marta Boffito; Adrian Wildfire; Andrew Hill; David Back; Saye Khoo; Mark Nelson; Graeme Moyle; Brian Gazzard; Anton Pozniak
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2004;48(7):2388-93.
2004: Antonio Pires; Gareth Hardy; Brian Gazzard; Frances Gotch; Nesrina Imami
Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs.
Journal of acquired immune deficiency syndromes (1999) 2004;36(3):783-90.
2004: Marta Boffito; Laura Dickinson; Andrew Hill; David Back; Graeme Moyle; Mark Nelson; Christopher Higgs; Carl Fletcher; Sundhiya Mandalia; Brian Gazzard; Anton Pozniak
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
Antiviral therapy 2004;9(3):423-9.
2004: Justin Stebbing; Steve Patterson; Simon Portsmouth; Claire Thomas; Robert Glassman; Adrian Wildfire; Frances Gotch; mark bower; Mark Nelson; Brian Gazzard
Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients.
Cell research 2004;14(3):251-6.
2004: Justin Stebbing; Brian Gazzard; Sundhiya Mandalia; Alastair Teague; Ashita Waterston; Vanessa Marvin; Mark Nelson; mark bower
Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2177-83.
2004: Justin Stebbing; Brian Gazzard; Daniel C Douek
Where does HIV live?
The New England journal of medicine 2004;350(18):1872-80.
2004: Tom Powles; mark bower; J Shamash; Justin Stebbing; J Ong; G Daugaard; A De Ruiter; M Johnson; M Fisher; J Anderson; Mark Nelson; Brian Gazzard; T Oliver
Outcome of patients with HIV-related germ cell tumours: a case-control study.
British journal of cancer 2004;90(8):1526-30.
2004: Alan Winston; Anton Pozniak; Sundhiya Mandalia; Brian Gazzard; Deenan Pillay; Mark Nelson
Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.
AIDS (London, England) 2004;18(6):949-51.
2004: T Powles; J Powles; Mark Nelson; A Sandison; David Peston; J Buchannan; S Mandalia; Brian Gazzard; mark bower
Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus.
The Journal of laryngology and otology 2004;118(3):207-12.
2004: Gareth Hardy; S Worrell; P Hayes; C M Barnett; D Glass; Jeffrey Pido-Lopez; Nesrina Imami; Richard Aspinall; J Dutton; Brian Gazzard; A M Peters; Frances M Gotch
Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV-1 infection.
HIV medicine 2004;5(2):67-73.
2004: Justin Stebbing; Mark Nelson; Chloe Orkin; Sundhiya Mandalia; mark bower; Anton Pozniak; Brian Gazzard
A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
The Journal of antimicrobial chemotherapy 2004;53(3):501-5.
2004: Justin Stebbing; Brian Gazzard; Steve Patterson; mark bower; Dhayaneethie Perumal; Mark Nelson; Andrew McMichael; Graham Ogg; Agamemnon Epenetos; Frances Gotch; Philip Savage
Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination.
Blood 2004;103(5):1791-5.
2004: Alan Winston; Anton Pozniak; Nicola Smith; Carl Fletcher; Sundhiya Mandalia; Darmishta Parmar; Sarah Gibbons; David Back; Brian Gazzard; Mark Nelson
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
AIDS (London, England) 2004;18(3):572-4.
2004: Justin Stebbing; Simon Portsmouth; Mark Nelson; Sundhiya Mandalia; Hala Kandil; Nic Alexander; Liz Davies; Cathryn Brock; mark bower; Brian Gazzard
The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma.
International journal of cancer. Journal international du cancer 2004;108(4):631-3.
2004: Antonio Pires; Jeffrey Pido-Lopez; Graeme Moyle; Brian Gazzard; Frances Gotch; Nesrina Imami
Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy.
Antiviral therapy 2004;9(1):67-75.
2004: Justin Stebbing; Brian Gazzard; Tom Newsom-Davis; Mark Nelson; Steve Patterson; Frances Gotch; Sundhiya Mandalia; mark bower
Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma.
International journal of cancer. Journal international du cancer 2004;108(3):473-4.
2004: Justin Stebbing; Philip Savage; Steve Patterson; Brian Gazzard
All for CD91 and CD91 for all.
The Journal of antimicrobial chemotherapy 2004;53(1):1-3.
2003: Martin R Goodier; Nesrina Imami; G Moyle; Brian Gazzard; Frances Gotch
Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone.
Clinical and experimental immunology 2003;134(3):470-6.
2003: Sunil Shaunak; Ian Teo; Ji-won Choi; Brian Gazzard
HIV DNA two long terminal repeat circles: observations and interpretations.
AIDS (London, England) 2003;17(15):2273-4.
2003: Hala Kandil; Justin Stebbing; Brian Gazzard; Simon Portsmouth
Innate and adaptive immunological insights into HIV pathogenesis.
International journal of STD & AIDS 2003;14(10):652-5.
2003: D Datta; Graeme Moyle; Sundhiya Mandalia; Brian Gazzard
Matched case-control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy.
HIV medicine 2003;4(4):311-4.
2003: Anton Pozniak; Brian Gazzard; Jane Anderson; Abdel G Babiker; Duncan Churchill; S Collins; Martin Fisher; Margaret Johnson; Saye Khoo; Clifford Leen; Clive Loveday; Graeme Moyle; Mark Nelson; B Peter; A Phillips; Deenan Pillay; Edmund Wilkins; Ian Williams; Mike Youle
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
HIV medicine 2003;4 Suppl 1():1-41.
2003: Justin Stebbing; Brian Gazzard; Ornella Flore; Claire Thomas; Adel Benlahrech; Sundhiya Mandalia; mark bower; Frances Gotch; Steve Patterson
Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma.
AIDS (London, England) 2003;17(13):1998-2000.
2003: Justin Stebbing; Brian Gazzard; Simon Portsmouth; Frances Gotch; Louise Kim; mark bower; Sundhiya Mandalia; Robert Binder; Pramod Srivastava; Steve Patterson
Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor.
Blood 2003;102(5):1806-14.
2003: Tom Powles; C Thirwell; Tom Newsom-Davis; Mark Nelson; P Shah; S Cox; Brian Gazzard; mark bower
Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?
British journal of cancer 2003;89(3):457-9.
2003: Simon Portsmouth; Justin Stebbing; Jas Gill; Sundhiya Mandalia; Mark Bower; Mark Nelson; mark bower; Brian Gazzard
A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
AIDS (London, England) 2003;17(11):F17-22.
2003: Heather Donaghy; Brian Gazzard; Frances Gotch; Steve Patterson
Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1.
Blood 2003;101(11):4505-11.
2003: Tom Powles; mark bower; G Daugaard; J Shamash; A De Ruiter; M Johnson; M Fisher; J Anderson; Sundhiya Mandalia; Justin Stebbing; Mark Nelson; Brian Gazzard; T Oliver
Multicenter study of human immunodeficiency virus-related germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):1922-7.
2003: Justin Stebbing; Brian Gazzard; Louise Kim; Simon Portsmouth; Adrian Wildfire; Ian Teo; Mark Nelson; mark bower; Frances Gotch; Sunil Shaunak; Pramod Srivastava; Steve Patterson
The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors.
Blood 2003;101(10):4000-4.
2003: Justin Stebbing; Simon Portsmouth; Brian Gazzard
How does HAART lead to the resolution of Kaposi's sarcoma?
The Journal of antimicrobial chemotherapy 2003;51(5):1095-8.
2003: Debashish Sarker; Christina Thirlwell; Mark Nelson; Brian Gazzard; mark bower
Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma.
AIDS (London, England) 2003;17(6):861-5.
2003: Justin Stebbing; Simon Portsmouth; Frances Gotch; Brian Gazzard
Kaposi's sarcoma--an update.
International journal of STD & AIDS 2003;14(4):225-7.
2003: John Morlese; Ian Teo; Ji-won Choi; Brian Gazzard; Sunil Shaunak
Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART.
AIDS (London, England) 2003;17(5):679-83.
2003: mark bower; Tom Powles; Mark Nelson; Pallav Shah; Sarah Cox; Sundhiya Mandelia; Brian Gazzard
HIV-related lung cancer in the era of highly active antiretroviral therapy.
AIDS (London, England) 2003;17(3):371-5.
2003: Jeffrey Pido-Lopez; Catherine Burton; Gareth Hardy; Antonio Pires; Ann Sullivan; Brian Gazzard; Richard Aspinall; Frances Gotch; Nesrina Imami
Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune).
AIDS research and human retroviruses 2003;19(2):103-9.
2003: Paul Fox; Justin Stebbing; Simon Portsmouth; Alan Winston; Nick Frances; Mark Nelson; Brian Gazzard; mark bower
Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapy.
AIDS (London, England) 2003;17(2):279-80.
2003: Mark Nelson; Simon Portsmouth; Justin Stebbing; M Atkins; A Barr; G Matthews; Deenan Pillay; Martin Fisher; mark bower; Brian Gazzard
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
AIDS (London, England) 2003;17(1):F7-10.
2003: Simon Portsmouth; Justin Stebbing; Brian Gazzard
Current treatment of HIV infection.
Current topics in medicinal chemistry 2003;3(13):1458-66.
2002: Jas Gill; Dimitra Bourboulia; John Wilkinson; Peter Hayes; Alethea Cope; Anne-Geneviève Marcelin; Vincent Calvez; Frances Gotch; Chris Boshoff; Brian Gazzard
Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
Journal of acquired immune deficiency syndromes (1999) 2002;31(4):384-90.
2002: Ben Esdaile; Matt Davis; Simon Portsmouth; Debashis Sarker; Mark Nelson; Brian Gazzard; mark bower
The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma.
AIDS (London, England) 2002;16(17):2344-7.
2002: Catherine T Burton; Gareth A D Hardy; Ann K Sullivan; Mark R Nelson; Brian Gazzard; Frances M Gotch; Nesrina Imami
Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, beta-chemokines and IL-16 secretion in HIV-1 infection.
Clinical and experimental immunology 2002;130(2):286-92.
2002: Alan Winston; Sundhiya Mandalia; Deenan Pillay; Brian Gazzard; Anton Pozniak
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
AIDS (London, England) 2002;16(15):2087-9.
2002: Sundhiya Mandalia; D Parmar; Martin Fisher; Anton Pozniak; A Tang; Mike Youle; Brian Gazzard; Eduard J Beck
Naively changing HAART.
HIV medicine 2002;3(4):254-62.
2002: Nesrina Imami; Antonio Pires; Gareth Hardy; Jamie Wilson; Brian Gazzard; Frances Gotch
A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection.
Journal of virology 2002;76(18):9011-23.
2002: John Wilkinson; Alethea Cope; Jas Gill; Dimitra Bourboulia; Peter Hayes; Nesrina Imami; Toru Kubo; Anne-Geneviève Marcelin; Vincent Calvez; Robin Weiss; Brian Gazzard; Chris Boshoff; Frances Gotch
Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.
Journal of virology 2002;76(6):2634-40.
2002: Jeffrey Pido-Lopez; A Pires; M Nelson; E O'Moore; M Fisher; Brian Gazzard; Richard Aspinall; Frances Gotch; Nesrina Imami
Thymic activity in late-stage HIV-1 infected individuals receiving highly active antiretroviral therapy: potential effect of steroid therapy.
HIV medicine 2002;3(1):56-61.
2001: Nesrina Imami; Gareth Hardy; C Burton; A Pires; Jeffrey Pido-Lopez; R Moss; Brian Gazzard; Frances Gotch
Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination.
Immunology letters 2001;79(1-2):63-76.
2001: Heather Donaghy; Anton Pozniak; Brian Gazzard; N Qazi; J Gilmour; Frances Gotch; Steve Patterson
Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load.
Blood 2001;98(8):2574-6.
2000: J D Wilson; Nesrina Imami; A Watkins; J Gill; Phillip Hay; Brian Gazzard; M Westby; Frances M Gotch
Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease.
The Journal of infectious diseases 2000;182(3):792-8.
2000: Philippa J Easterbrook; L M Yu; E Goetghebeur; Fiona Boag; K McLean; Brian Gazzard
Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.
AIDS (London, England) 2000;14(5):561-71.
2000: D Sharpstone; M Phelan; Brian Gazzard
Differential metabolic response in AIDS-related chronic protozoal diarrhoea.
HIV medicine 2000;1(2):102-6.
2000: Mark E Sharkey; Ian Teo; Thomas C Greenough; Natalia Sharova; Katherine Luzuriaga; John L Sullivan; R P Bucy; Leondios G Kostrikis; A Haase; C Veryard; R E Davaro; Sarah H Cheeseman; Jennifer S Daly; C Bova; Richard Ellison; B Mady; Kwan Kew Lai; G Moyle; M Nelson; Brian Gazzard; Sunil Shaunak; Mario Stevenson
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.
Nature medicine 2000;6(1):76-81.
1999: Nesrina Imami; Christos Antonopoulos; Gareth A D Hardy; Brian Gazzard; Frances M Gotch
Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy.
AIDS research and human retroviruses 1999;15(17):1499-508.
1999: mark bower; P Fox; K Fife; Jas Gill; Mark Nelson; Brian Gazzard
Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.
AIDS (London, England) 1999;13(15):2105-11.
1999: Nesrina Imami; Gareth A D Hardy; Mark R Nelson; S Morris-Jones; R Al-Shahi; Christos Antonopoulos; Brian Gazzard; Frances M Gotch
Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy.
Clinical and experimental immunology 1999;118(1):78-86.
1999: D Sharpstone; C Murray; H Ross; M Phelan; R Crane; A C Lepri; Mark Nelson; Brian Gazzard
The influence of nutritional and metabolic status on progression from asymptomatic HIV infection to AIDS-defining diagnosis.
AIDS (London, England) 1999;13(10):1221-6.
1999: D Sharpstone; PJ Neild; R Crane; C Taylor; C Hodgson; Roy Sherwood; Brian Gazzard; Ingvar Bjarnason
Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea.
Gut 1999;45(1):70-6.
1998: Brian Gazzard; Graeme Moyle
1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee.
Lancet 1998;352(9124):314-6.
1998: A Mocroft; Mike Youle; Andrew N Phillips; R Halai; Philippa Easterbrook; Margaret A Johnson; Brian Gazzard
The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.
Archives of internal medicine 1998;158(5):491-7.
1998: AW Rowbottom; M W Lepper; D Sharpstone; Brian Gazzard
Cytomegalovirus (CMV) infection in AIDS patients is associated with a CD3 receptor-mediated T cell hyporesponsiveness.
Clinical and experimental immunology 1998;111(3):559-63.
1998: Brian Gazzard
The role of proteinases in the treatment of HIV infection.
International journal of STD & AIDS 1998;9 Suppl 1():28-31.
1997: D Sharpstone; H Ross; M Hancock; M Phelan; R Crane; Brian Gazzard
Indirect calorimetry, body composition and small bowel function in asymptomatic HIV-seropositive women.
International journal of STD & AIDS 1997;8(11):700-3.
1997: D Sharpstone; AW Rowbottom; N Francis; G Tovey; D Ellis; M Barrett; Brian Gazzard
Thalidomide: a novel therapy for microsporidiosis.
Gastroenterology 1997;112(6):1823-9.
1997: Amanda Mocroft; Mike Youle; J Morcinek; Caroline A Sabin; Brian Gazzard; Margaret A Johnson; Andrew N Phillips
Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.
BMJ (Clinical research ed.) 1997;314(7078):409-13.
1996: Brian Gazzard
What we know so far.
AIDS (London, England) 1996;10 Suppl 1():S3-7.
1996: Amanda Mocroft; Mike Youle; Brian Gazzard; J Morcinek; R Halai; Andrew N Phillips
Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.
AIDS (London, England) 1996;10(10):1101-5.
1996: D Sharpstone; AW Rowbottom; Mark Nelson; Brian Gazzard
Faecal alpha 1 antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals.
Gut 1996;38(2):206-10.
1995: D Sharpstone; AW Rowbottom; Mark Nelson; Brian Gazzard
The treatment of microsporidial diarrhoea with thalidomide.
AIDS (London, England) 1995;9(6):658-9.
1993: A Burgess; M Dayer; J Catalan; D Hawkins; Brian Gazzard
The reliability and validity of two HIV-specific health-related Quality-of-Life measures: a preliminary analysis.
AIDS (London, England) 1993;7(7):1001-8.